Featured News
AI Uncovers New Treatment Opportunities
Innovative research opens the door for lupus and autoimmune care
In partnership with Pioneering Medicines, Charles River and Valo Health have identified a promising therapeutic target for lupus using AI-powered Logica®. The discovery is the first using this platform, which translates biological insights into optimized preclinical assets. It marks a key milestone in our collaboration and demonstrates the potential of AI to accelerate drug development and bring new treatments to patients faster, because every moment matters.
By leveraging Logica, we analyzed vast biological datasets and identified a novel target to advance autoimmune diseases, an area with significant unmet medical need.
A result of a strategic partnership between Charles River and Valo Health, Logica is the industry’s first computation-powered, unified target-to-candidate offering. It leverages the integration of Valo Health’s AI-powered Opal Computational Platform™ and our leading expertise in drug discovery and preclinical development.